Skip to main content
Clinical Trials/CTRI/2023/11/060182
CTRI/2023/11/060182
Not yet recruiting
Phase 4

A prospective, open-label, single-arm clinical study to evaluate the performance & safety of Eyevisc 2.4% OVD in patient undergoing cataract surgery - NI

Biotech Ophthalmics Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: H251- Age-related nuclear cataract
Sponsor
Biotech Ophthalmics Pvt Ltd
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Biotech Ophthalmics Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\) Unilateral/Bilateral
  • 2\) Age \= 45 year or greater.
  • 3\) Cataract for which phacoemulsification extraction and posterior
  • chamber IOL implantation was planned in at least one eye of the
  • patient. 4\) Clear intraocular media other than cataract.
  • 5\) Signed informed consent. 6\) Patient who are willing to attend all the regular follow\-up
  • examinations as per the study schedule.
  • 7\) Patients with Grade I to III cataract and used OVDs
  • 8\) Patients that have healthy eyes excluding the formation of cataract.
  • 9\) Given consent to use device related data for scientific purpose.

Exclusion Criteria

  • 1\) Concurrent participation or participation in the last 30 days in any
  • other clinical trial.
  • 2\) History of previous steroid \- induced IOP
  • 3\) Patient with pigment dispersion syndrome
  • 4\) Taking medications that may affect vision, IOP, or ease of cataract
  • surgery (e.g., Flomax, glaucoma medications, etc.)
  • 5\) Acute or chronic disease or illness that would increase risk or
  • confound study results (e.g., diabetes mellitus,
  • immunocompromised, etc.).
  • 6\) Uncontrolled systemic or ocular disease.

Outcomes

Primary Outcomes

Not specified

Similar Trials